TABLE 1.

Genetic scores for the prediction of MASH.

Reference	Score	Outcome	AUROC	Sensitivity	Specificity
Hyysalo et al.	NASH score: PNPLA3 genotype, AST and fasting insulin	Prediction of MASH	0.774 (95% C.I.: 0.709, 0.839) in Finns; 0.759 (95% C.I.: 0.711, 0.807) in Italians	71.6% in Finns; 39% in Italians	73.5% in Finns; 89% in Italians
Koo et al.	NASH PT scores: PNPLA3 and TM6SF2 genotypes, diabetes status, HOMA‐IR, AST and hsCRP	Prediction of MASH	0.859 (95% CI, 0.817–0.901)	0.881	0.684
Zhou et al.	NASH ClinLipMet score: AST, fasting insulin, PNPLA3 genotype, glutamate, isoleucine, glycine, lysophosphatidylcholine 16:0, phosphoethanolamine 40:6	Prediction of MASH	0.866 (95% CI, 0.820–0.913)	85.5%	72.1%
Paternostro et al.	Age, sex, BMI, diabetes, ALT (baseline model) + PNPLA3 genotype	Prediction of NAS ≥5	0.766
	Baseline model + HSB17B13 genotype	Prediction of NAS ≥5	0.766
	Baseline model + PNPLA3 and HSB17B13 genotype	Prediction of NAS ≥5	0.775
	Baseline model + TM6SF2 genotype	Prediction of NAS ≥5	0.762
	Age, sex, BMI, diabetes (baseline model for advanced fibrosis) + PNPLA3 genotype	Prediction of advanced fibrosis	0.789
	Baseline model for advanced fibrosis + TM6SF2 genotype	Prediction of advanced fibrosis	0.786
	Baseline model for advanced fibrosis + HSD17B13 genotype	Prediction of advanced fibrosis	0.777

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUROC, area under the receiver‐operating characteristic curve; BMI, body mass index; MASH, metabolic dysfunction‐associated steatohepatitis; NAS, NAFLD activity score.